A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China
Latest Information Update: 07 Jul 2025
At a glance
- Drugs GenSci 120 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors GeneScience Pharmaceuticals
Most Recent Events
- 03 Jul 2025 Status changed from planning to not yet recruiting.
- 25 Feb 2025 New trial record
- 17 Jan 2025 According to a Changchun GeneScience Pharmaceutical Co., Ltd. media release, company announced that the National Medical Products Administration (NMPA) has approved an IND application for the PD-1 agonist GenSci120 for the treatment of Rheumatoid Arthritis.